Grail, Inc.
Case Overview
| Lead Plaintiff Deadline: | Lead Plaintiff Deadline: 08/04/2026 |
| Status: | Status: Investigating |
| Company Name: | Company Name: Grail, Inc. |
| Court: | Court: Northern District of California |
| Case Number: | Case Number: 4:26cv05428 |
| Class Period: | Class Period: 05/13/2025 - 02/19/2026 |
| Ticker: | Ticker: GRAL |
| Related Attorneys: | Lead Attorneys: Thomas W. Elrod |
| Related Practices: | Related Practices: Securities |
The law firm of Kirby McInerney LLP announces that a class action lawsuit has been filed on behalf of investors who acquired Grail, Inc. (“Grail” or the “Company”) (NASDAQ:GRAL) securities during the period of May 13, 2025 through February 19, 2026, inclusive (“the Class Period”).
The lawsuit alleges that the Company provided overwhelmingly positive statements to investors while, at the same time, disseminating materially false and misleading statements and/or concealing material adverse facts concerning the true state of GRAIL's NHS-Galleri trial following the reveal of the top-line results covering the first screening round. Notably, as Grail have since attested, the trial as executed within the three-year follow-up period was insufficient to demonstrate the achievability of a reduction in Stage III-IV cancers; defendants disclosed the trial period, and thus the screening duration, was apparently insufficient to demonstrate whether the primary endpoint was achievable. Grail further repeatedly refused to provide detailed topline results or other data from the NHS-Galleri study, potentially concealing known trendlines which arguably suggested either a longer timeline would be necessary or otherwise that the probability of achieving the statistical reduction in Stage III & IV cancers by the trial's end had been reduced.
On February 19, 2026, Grail announced that the "primary endpoint of statistically significant Stage III-IV reduction was not observed" in the NHS-Galleri Trial. The Company attributed this shortcoming, in part, on "probably need[ing] a longer follow-up time to be able to [compare the study arms] adequately." On this news, the price of Grail shares declined by $51.32 per share, or approximately 51%, from $101.53 per share on February 19, 2026 to close at $50.21 on February 20, 2026.